Literature DB >> 26645049

Targeting Transcription Factors in Cancer.

Anand S Bhagwat1, Christopher R Vakoc1.   

Abstract

Transcription factors (TFs) are commonly deregulated in the pathogenesis of human cancer and are a major class of cancer cell dependencies. Consequently, targeting of TFs can be highly effective in treating particular malignancies, as highlighted by the clinical efficacy of agents that target nuclear hormone receptors. In this review we discuss recent advances in our understanding of TFs as drug targets in oncology, with an emphasis on the emerging chemical approaches to modulate TF function. The remarkable diversity and potency of TFs as drivers of cell transformation justifies a continued pursuit of TFs as therapeutic targets for drug discovery.

Entities:  

Year:  2015        PMID: 26645049      PMCID: PMC4669894          DOI: 10.1016/j.trecan.2015.07.001

Source DB:  PubMed          Journal:  Trends Cancer        ISSN: 2405-8025


  99 in total

Review 1.  Lessons from the cancer genome.

Authors:  Levi A Garraway; Eric S Lander
Journal:  Cell       Date:  2013-03-28       Impact factor: 41.582

2.  Opposing regulation of BIM and BCL2 controls glucocorticoid-induced apoptosis of pediatric acute lymphoblastic leukemia cells.

Authors:  Duohui Jing; Vivek A Bhadri; Dominik Beck; Julie A I Thoms; Nurul A Yakob; Jason W H Wong; Kathy Knezevic; John E Pimanda; Richard B Lock
Journal:  Blood       Date:  2014-10-21       Impact factor: 22.113

Review 3.  Molecular genetics of prostate cancer: new prospects for old challenges.

Authors:  Michael M Shen; Cory Abate-Shen
Journal:  Genes Dev       Date:  2010-09-15       Impact factor: 11.361

4.  Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer.

Authors:  Irfan A Asangani; Vijaya L Dommeti; Xiaoju Wang; Rohit Malik; Marcin Cieslik; Rendong Yang; June Escara-Wilke; Kari Wilder-Romans; Sudheer Dhanireddy; Carl Engelke; Mathew K Iyer; Xiaojun Jing; Yi-Mi Wu; Xuhong Cao; Zhaohui S Qin; Shaomeng Wang; Felix Y Feng; Arul M Chinnaiyan
Journal:  Nature       Date:  2014-04-23       Impact factor: 49.962

5.  Selective inhibition of tumor oncogenes by disruption of super-enhancers.

Authors:  Jakob Lovén; Heather A Hoke; Charles Y Lin; Ashley Lau; David A Orlando; Christopher R Vakoc; James E Bradner; Tong Ihn Lee; Richard A Young
Journal:  Cell       Date:  2013-04-11       Impact factor: 41.582

6.  An F876L mutation in androgen receptor confers genetic and phenotypic resistance to MDV3100 (enzalutamide).

Authors:  Manav Korpal; Joshua M Korn; Xueliang Gao; Daniel P Rakiec; David A Ruddy; Shivang Doshi; Jing Yuan; Steve G Kovats; Sunkyu Kim; Vesselina G Cooke; John E Monahan; Frank Stegmeier; Thomas M Roberts; William R Sellers; Wenlai Zhou; Ping Zhu
Journal:  Cancer Discov       Date:  2013-07-10       Impact factor: 39.397

7.  Growth factor stimulation induces a distinct ER(alpha) cistrome underlying breast cancer endocrine resistance.

Authors:  Mathieu Lupien; Clifford A Meyer; Shannon T Bailey; Jérôme Eeckhoute; Jennifer Cook; Thomas Westerling; Xiaoyang Zhang; Jason S Carroll; Daniel R Rhodes; X Shirley Liu; Myles Brown
Journal:  Genes Dev       Date:  2010-10-01       Impact factor: 11.361

Review 8.  Targeting the adaptive molecular landscape of castration-resistant prostate cancer.

Authors:  Alexander W Wyatt; Martin E Gleave
Journal:  EMBO Mol Med       Date:  2015-07       Impact factor: 12.137

Review 9.  The evolution of prostate cancer therapy: targeting the androgen receptor.

Authors:  Jeanny B Aragon-Ching
Journal:  Front Oncol       Date:  2014-10-24       Impact factor: 6.244

Review 10.  Estrogen receptor coregulators and pioneer factors: the orchestrators of mammary gland cell fate and development.

Authors:  Bramanandam Manavathi; Venkata S K Samanthapudi; Vijay Narasimha Reddy Gajulapalli
Journal:  Front Cell Dev Biol       Date:  2014-08-12
View more
  97 in total

Review 1.  Super-Enhancer-Driven Transcriptional Dependencies in Cancer.

Authors:  Satyaki Sengupta; Rani E George
Journal:  Trends Cancer       Date:  2017-04-12

Review 2.  Super-enhancer function and its application in cancer targeted therapy.

Authors:  Faqing Tang; Zongbei Yang; Yuan Tan; Yuejin Li
Journal:  NPJ Precis Oncol       Date:  2020-02-12

3.  Targeting TAZ-Driven Human Breast Cancer by Inhibiting a SKP2-p27 Signaling Axis.

Authors:  He Shen; Nuo Yang; Alexander Truskinovsky; Yanmin Chen; Ashley L Mussell; Norma J Nowak; Lester Kobzik; Costa Frangou; Jianmin Zhang
Journal:  Mol Cancer Res       Date:  2018-09-20       Impact factor: 5.852

Review 4.  Chemical modulation of transcription factors.

Authors:  Bianca Wiedemann; Jörn Weisner; Daniel Rauh
Journal:  Medchemcomm       Date:  2018-07-11       Impact factor: 3.597

5.  The AP-1 transcription factor JunB is essential for multiple myeloma cell proliferation and drug resistance in the bone marrow microenvironment.

Authors:  F Fan; M H Bashari; E Morelli; G Tonon; S Malvestiti; S Vallet; M Jarahian; A Seckinger; D Hose; L Bakiri; C Sun; Y Hu; C R Ball; H Glimm; M Sattler; H Goldschmidt; E F Wagner; P Tassone; D Jaeger; K Podar
Journal:  Leukemia       Date:  2016-11-28       Impact factor: 11.528

Review 6.  FoxO transcription factors in cancer metabolism.

Authors:  Raj Kumar Yadav; Anoop Singh Chauhan; Li Zhuang; Boyi Gan
Journal:  Semin Cancer Biol       Date:  2018-01-05       Impact factor: 15.707

7.  CIC-DUX4 oncoprotein drives sarcoma metastasis and tumorigenesis via distinct regulatory programs.

Authors:  Ross A Okimoto; Wei Wu; Shigeki Nanjo; Victor Olivas; Yone K Lin; Rovingaile Kriska Ponce; Rieko Oyama; Tadashi Kondo; Trever G Bivona
Journal:  J Clin Invest       Date:  2019-07-22       Impact factor: 14.808

8.  ETV4 and AP1 Transcription Factors Form Multivalent Interactions with three Sites on the MED25 Activator-Interacting Domain.

Authors:  Simon L Currie; Jedediah J Doane; Kathryn S Evans; Niraja Bhachech; Bethany J Madison; Desmond K W Lau; Lawrence P McIntosh; Jack J Skalicky; Kathleen A Clark; Barbara J Graves
Journal:  J Mol Biol       Date:  2017-07-17       Impact factor: 5.469

9.  A CK1α Activator Penetrates the Brain and Shows Efficacy Against Drug-resistant Metastatic Medulloblastoma.

Authors:  Jezabel Rodriguez-Blanco; Bin Li; Jun Long; Chen Shen; Fan Yang; Darren Orton; Sara Collins; Noriyuki Kasahara; Nagi G Ayad; Heather J McCrea; Martine F Roussel; William A Weiss; Anthony J Capobianco; David J Robbins
Journal:  Clin Cancer Res       Date:  2018-11-28       Impact factor: 12.531

10.  Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.

Authors:  Victoria E Clark; Akdes Serin Harmancı; Hanwen Bai; Mark W Youngblood; Tong Ihn Lee; Jacob F Baranoski; A Gulhan Ercan-Sencicek; Brian J Abraham; Abraham S Weintraub; Denes Hnisz; Matthias Simon; Boris Krischek; E Zeynep Erson-Omay; Octavian Henegariu; Geneive Carrión-Grant; Ketu Mishra-Gorur; Daniel Durán; Johanna E Goldmann; Johannes Schramm; Roland Goldbrunner; Joseph M Piepmeier; Alexander O Vortmeyer; Jennifer Moliterno Günel; Kaya Bilgüvar; Katsuhito Yasuno; Richard A Young; Murat Günel
Journal:  Nat Genet       Date:  2016-08-22       Impact factor: 38.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.